hiv-1 integrase

HIV-1 integrase inhibitor 7 is a potent inhibitor of HIV-1 integrase (IC50: 33.3 nM).

Hiv-1 integrase inhibitor is an effective anti-HIV drug.

HIV-1 integrase inhibitor 3 is an HIV-1 integrase strand transfer (INST) inhibitor with an IC50 of 2.7 nM.

HIV-1 integrase inhibitor 4 is an HIV-1 integrase strand transfer (INST) inhibitor with an IC50 of 3.7 nM.

HIV-1integrase inhibitor 12 (Compound 17) is an inhibitor of HIV-1 integrase with an IC50 of 1.4 nM. It effectively inhibits both HIV-1WT and HIV-1T125A with IC50 values of 7.4 nM and 120 nM, respectively. This compound exhibits metabolic stability and Caco-2 permeability in rats, with favorable pharmacokinetic properties, including good bioavailability (64%) and low clearance rate (0.16 L/hr/kg).

HIV-1 integrase inhibitor 13 (Compound 15) is an inhibitor of HIV-1 integrase, with an IC50 value of 1.8 nM. It can inhibit HIV-1WT and HIV-1T125A, with IC50 values of 21 and 580 nM, respectively.

HIV-1 integrase inhibitor 9 (compound 8a) is a potent inhibitor of HIV-1 RNase H (IC50: 12.3 μM) with antiviral effects.

HIV-1 Integrase Inhibitor 10, an orally active allosteric integrase inhibitor (ALLINI), effectively inhibits the NLRepRluc virus's viral outgrowth in MT-2 cells, exhibiting EC50 values of 3-5 nM. This compound is utilized in the research of Human Immunodeficiency Virus-1 (HIV-1).

HIV-1 integrase inhibitor 11 (compound 5) effectively inhibits HIV-1 integrase (HIV-1integrase), with an IC50 of 125 μM.

HIV-1 integrase inhibitor 8 is an inhibitor of HIV-1 integrase, a critical enzyme necessary for the integration step in HIV replication [1].

(S)-BI-1001 is an active S-enantiomer of BI-1001. (S)-BI-1001 has antiviral potency against HIV-1 integrase (IC50: 28 nM, and EC50: 450 nM and a Kd: 4.7 μM).

Lavendustin B is a Tyrosine Kinase Inhibitor and an inhibitor of HIV-1 integrase (IN) interaction with its cognate cellular cofactor, lens epithelium-derived growth factor (LEDGF/p75).

Bictegravir Sodium (GS-9883 Sodium) is a potent inhibitor of HIV-1 integrase, with an IC50 of 7.5 nM. Bictegravir Sodium exhibits potent and selective anti-HIV activity and low cytotoxicity

HIV-1 integrase inhibitor 2 is used for the treatment of human immunodeficiency virus (HIV) infection.

Bictegravir (GS-9883) is a potent inhibitor of HIV-1 integrase with an IC50 value of 7.5 nM.

BMS-707035 is a specific HIV-I integrase (IN) inhibitor with IC50 of 15 nM. Phase 2.

L-Chicoric Acid (trans-Caffeoyltartaric acid) has been shown to inhibit hyaluronidase and HIV-1 integrase, and to possess phagoeytosis stimulatory activity in vitro and in vivo and antiviral acitivy. L-Chicoric acid may reduce acute alcohol-induced steatosis in mice through interfering with the induction of iNOS and iNOS-dependent signaling cascades in the liver. 3. L-Chicoric acid inhibited cell viability and induced apoptosis in 3T3-L1 preadipocytes which was characterized by chromatin condensation and poly ADP-ribose-polymerase (PARP) cleavage.

Cichoric Acid (Dicaffeoyltartaric acid) is a potent inhibitor of human immunodeficiency virus type-1 (HIV-1) integrase and the replication in tissues. It also a class of cannabinomimetics with CB2 receptor-dependent and independent.

GSK-364735 is a human immunodeficiency virus type 1 integrase (HIV-1 IN) inhibitor with antiviral activity and is used in the study of retroviral infections.

Dolutegravir intermediate-1 (1-(2,2-dimethoxyethyl)-5-methoxy-6-(methoxycarbonyl)-4-oxo-1,4-dihydropyridine-3-carboxylic acid) is a new synthetic Dolutegravir intermediate. Dolutegravir is an integrase inhibitor developed for the treatment of human immunodeficiency virus (HIV)-1 infection.

AI 3-16787 is an HIV-1 integrase inhibitor exhibiting inhibitory activity against strand transfer in the presence of Mn²⁺.

Dolutegravir sodium (GSK-1349572A) salt(DTG; GSK1349572) is an HIV integrase inhibitor(IC50: 2.7 nM), modest activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H.

Cabotegravir (S/GSK1265744) (GSK744, GSK1265744) is a long-acting HIV integrase inhibitor and inhibits the HIV-1 integrase catalyzed strand transfer reaction (IC50: 3.0 nM).

Dolutegravir (GSK1349572) (IC50=2.7 nM), a two-metal-binding HIV integrase inhibitor, exhibits medium activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H.